- Home
- RSSS vs GNLX Comparison
RSSS vs GNLX Comparison
Compare RSSS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSSS
- GNLX
- Stock Information
- Founded
- RSSS 2006
- GNLX 2001
- Country
- RSSS United States
- GNLX United States
- Employees
- RSSS N/A
- GNLX N/A
- Industry
- RSSS Business Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RSSS Consumer Discretionary
- GNLX Health Care
- Exchange
- RSSS Nasdaq
- GNLX Nasdaq
- Market Cap
- RSSS 110.0M
- GNLX 128.0M
- IPO Year
- RSSS N/A
- GNLX 2023
- Fundamental
- Price
- RSSS $3.34
- GNLX $6.42
- Analyst Decision
- RSSS Strong Buy
- GNLX Strong Buy
- Analyst Count
- RSSS 1
- GNLX 4
- Target Price
- RSSS $5.00
- GNLX $17.75
- AVG Volume (30 Days)
- RSSS 108.7K
- GNLX 141.0K
- Earning Date
- RSSS 11-13-2025
- GNLX 11-13-2025
- Dividend Yield
- RSSS N/A
- GNLX N/A
- EPS Growth
- RSSS N/A
- GNLX N/A
- EPS
- RSSS 0.04
- GNLX N/A
- Revenue
- RSSS $49,057,981.00
- GNLX N/A
- Revenue This Year
- RSSS $5.79
- GNLX N/A
- Revenue Next Year
- RSSS $8.46
- GNLX N/A
- P/E Ratio
- RSSS $78.50
- GNLX N/A
- Revenue Growth
- RSSS 9.94
- GNLX N/A
- 52 Week Low
- RSSS $2.32
- GNLX $1.99
- 52 Week High
- RSSS $4.24
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- RSSS 46.06
- GNLX 78.30
- Support Level
- RSSS $3.11
- GNLX $4.17
- Resistance Level
- RSSS $3.65
- GNLX $5.72
- Average True Range (ATR)
- RSSS 0.17
- GNLX 0.44
- MACD
- RSSS -0.06
- GNLX 0.11
- Stochastic Oscillator
- RSSS 32.78
- GNLX 95.92
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.